Contraceptives Archives - Revista Brasileira de Ginecologia e Obstetrícia
, , , , , Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2022;44(7):710-718
, , , , , To describe the effects of combined oral contraceptives (COC) on the renin-angiotensin-aldosterone system (RAAS).
The findings of this study suggest that the COC promotes greater activation of the RAAS. Supporting the idea that its use is related to an increased risk of cardiovascular events, including systemic arterial hypertension.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2022;44(7):710-718
, , , , , To describe the effects of combined oral contraceptives (COC) on the renin-angiotensin-aldosterone system (RAAS).
The findings of this study suggest that the COC promotes greater activation of the RAAS. Supporting the idea that its use is related to an increased risk of cardiovascular events, including systemic arterial hypertension.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2005;27(12):726-730
DOI 10.1590/S0100-72032005001200004
PURPOSE: to study the influence of the use of oral contraceptives (OC) on the number of Langerhans' cells in women without cervical infection by human papillomavirus (HPV). METHODS: thirty women who presented abnormal cervical cytology and colposcopy-guided biopsy with samples of uterine cervix negative for HPV were selected. The absence of HPV DNA was confirmed by hybrid capture. Langerhans' cells were identified by immunohistochemistry using anti-S100 antigens. The cells visualized in light microscopy were counted using the Cytoviewer software. The nonparametric Wilcoxon rank sum test was employed for statistical analysis. RESULTS: the average number of Langerhans' cells in OC users was 320.7/mm² and in non-users 190.7/mm², this difference being statistically nonsignificant. In the intermediary layer of the cervical epithelium a tendency towards the increase of these cells was observed, with the averages 192.1/mm² for OC users and 93.4/mm² for non-users (p=0.05). CONCLUSIONS: the present study reports a tendency towards the increase in the number of the Langerhans' cells among OC users. This result suggests the OC may induce alterations in the number of Langerhans' cells, but considering the limited number of cases, more studies should be developed for a definitive conclusion.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2005;27(12):726-730
DOI 10.1590/S0100-72032005001200004
PURPOSE: to study the influence of the use of oral contraceptives (OC) on the number of Langerhans' cells in women without cervical infection by human papillomavirus (HPV). METHODS: thirty women who presented abnormal cervical cytology and colposcopy-guided biopsy with samples of uterine cervix negative for HPV were selected. The absence of HPV DNA was confirmed by hybrid capture. Langerhans' cells were identified by immunohistochemistry using anti-S100 antigens. The cells visualized in light microscopy were counted using the Cytoviewer software. The nonparametric Wilcoxon rank sum test was employed for statistical analysis. RESULTS: the average number of Langerhans' cells in OC users was 320.7/mm² and in non-users 190.7/mm², this difference being statistically nonsignificant. In the intermediary layer of the cervical epithelium a tendency towards the increase of these cells was observed, with the averages 192.1/mm² for OC users and 93.4/mm² for non-users (p=0.05). CONCLUSIONS: the present study reports a tendency towards the increase in the number of the Langerhans' cells among OC users. This result suggests the OC may induce alterations in the number of Langerhans' cells, but considering the limited number of cases, more studies should be developed for a definitive conclusion.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2003;25(7):475-479
DOI 10.1590/S0100-72032003000700003
PURPOSE: to study the effects of low-dose oral hormonal contraceptives (OHC) (<30 mg of ethynylestradiol) on the intraerythrocytic folate levels. METHODS: this was a prospective transversal study with 95 patients treated in the Family Planning Clinic of UNIFESP (Federal University of São Paulo). The control group (Condom group) consisted of patients using condom as their exclusive contraceptive method during the last 12 months, and the study groups consisted of patients using low-dose oral hormonal contraceptives, in the following way: OHC 3 group (three to six months of use), OHC 6 group (six to twelve months of use) and OHC 12 group (more than twelve months of use). Intraerythrocytic folate was determined by the ionic capture method. Analysis of variance and c² test were used for statistical analysis. RESULTS: the Condom group showed a rate of 44% of patients with folate lower than 186.0 ng/mL and the users of low-dose oral contraceptives showed a rate of 32% (OHC 3 group), 16% (OHC 6 group) and 31% (OHC 12 group). We did not find in the group using low-dose oral contraceptives a significant reduction in the average level of intraerythrocytic folate compared to the control group and there was no statistically significant difference (p=0.28) regarding time of use. CONCLUSION: we observed reduced levels of intraerythrocytic folate in a significant number (44%) of patients not using low-dose oral hormonal contraceptives. Their rates were similar to the lower limit considered to be normal by most authors, which points to a basal folate deficiency in the studied group. We did not observe any alteration in the level of intraerythrocytic folate in patients using low-dose oral hormonal contraceptives.
Summary
Revista Brasileira de Ginecologia e Obstetrícia. 2003;25(7):475-479
DOI 10.1590/S0100-72032003000700003
PURPOSE: to study the effects of low-dose oral hormonal contraceptives (OHC) (<30 mg of ethynylestradiol) on the intraerythrocytic folate levels. METHODS: this was a prospective transversal study with 95 patients treated in the Family Planning Clinic of UNIFESP (Federal University of São Paulo). The control group (Condom group) consisted of patients using condom as their exclusive contraceptive method during the last 12 months, and the study groups consisted of patients using low-dose oral hormonal contraceptives, in the following way: OHC 3 group (three to six months of use), OHC 6 group (six to twelve months of use) and OHC 12 group (more than twelve months of use). Intraerythrocytic folate was determined by the ionic capture method. Analysis of variance and c² test were used for statistical analysis. RESULTS: the Condom group showed a rate of 44% of patients with folate lower than 186.0 ng/mL and the users of low-dose oral contraceptives showed a rate of 32% (OHC 3 group), 16% (OHC 6 group) and 31% (OHC 12 group). We did not find in the group using low-dose oral contraceptives a significant reduction in the average level of intraerythrocytic folate compared to the control group and there was no statistically significant difference (p=0.28) regarding time of use. CONCLUSION: we observed reduced levels of intraerythrocytic folate in a significant number (44%) of patients not using low-dose oral hormonal contraceptives. Their rates were similar to the lower limit considered to be normal by most authors, which points to a basal folate deficiency in the studied group. We did not observe any alteration in the level of intraerythrocytic folate in patients using low-dose oral hormonal contraceptives.